ChromaDex Reports Second Quarter Ingredient Sales Grew 155% Year-Over-Year and 52% Sequentially
date:Aug 13, 2014
Hi5 Boost, and Hi5 Lean.
- In May 2014, ChromaDex announced the initiation of the second human clinical study for PURENERGY, its patented caffeine ingredient. The study will build on the results from the first PURENERGY human study, which was performed in the summer of 2013. The new clinical trial will study the bioavailability and pharmacokinetics of PURENERGY as compared to caffeine and pTeroPure pterostilbene alone at repeated doses.
- In June 2014, ChromaDex announced it had licensed exclusi
8/12 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/15 17:01